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Assessment of Video Capsule Endoscopy in the Management
of Acute Gastrointestinal Bleeding During the COVID-19 Pandemic
Shahrad Hakimian, MD; Daniel Raines, MD; George Reed, PhD; Mark Hanscom, MD; Lilia Stefaniwsky, MD; Matthew Petersile, MD; Prashanth Rau, MD;
Anne Foley, MS; David Cave, MD, PhD

Abstract
IMPORTANCE Evaluation of acute gastrointestinal (GI) bleeding using invasive endoscopic
procedures comprising the standard of care (SOC)—upper endoscopy and colonoscopy—can expose
the endoscopy staff to SARS-CoV-2. Video capsule endoscopy (VCE) does not generate aerosols and
only requires 1 person to manage the procedure.
OBJECTIVE To examine the safety of VCE for the initial evaluation of GI bleeding at the peak of the

Key Points
Question Can video capsule endoscopy
be safely used as an alternative to
standard endoscopic procedures for the
initial evaluation of gastrointestinal
bleeding during the COVID-19
pandemic?

COVID-19 pandemic to identify signs of active bleeding while minimizing patient and personnel

Findings In this cohort study of 146

exposure, saving personal protective equipment, and avoiding invasive or unnecessary procedures.

patients (74 with COVID-19), active
bleeding was more frequently identified

DESIGN, SETTING, AND PARTICIPANTS A multicenter (UMass Memorial Medical Center and

with video capsule endoscopy as the

Louisiana State University Health Sciences Center) retrospective cohort study including 146 patients

first strategy (59.5%) compared with

with COVID-19 who received VCE as the first-line diagnostic modality was conducted from March 15

conventional endoscopic evaluation

to June 15, 2020, compared with SOC in January 2020 for evaluation of GI bleeding. The association

(25.0%). The number of invasive

between treatment and outcomes was estimated using multivariable regression adjusting for

procedures was significantly decreased

potential confounders. Propensity score matching was used to verify the results.

with video capsule endoscopy without
increased risk of rebleeding or

MAIN OUTCOMES AND MEASURES The primary end point was detection of active bleeding or
stigmata of recent bleeding. Secondary end points included the number of patients requiring any
invasive procedures, number of additional procedures, rates of rebleeding and rehospitalization,
transfusion requirements, and mortality.

compromising safety.
Meaning The results of this study
suggest that video capsule endoscopy
can serve as a safe alternative to the
standard endoscopic evaluation of

RESULTS Among 146 patients, 92 (63.0%) were men; mean (SD) age was 64.93 (14.13) years in the
COVID-19 group and 61.33 (13.39) years in the SOC group. Active bleeding or stigmata of recent
bleeding was observed in 44 (59.5%) patients in the COVID-19 group compared with 18 (25.0%) in
the SOC group (adjusted odds ratio, 5.23; 95% CI, 2.23 to 12.27). Only 36 patients (48.7%) in the

gastrointestinal bleeding because it
reduces the number of invasive
procedures, personnel involved, and use
of personal protective equipment.

COVID-19 group required any invasive procedure during the hospitalization compared with 70
(97.2%) in the SOC group (adjusted odds ratio, 0.01; 95% CI, 0.001 to 0.08). The mean (SD) number
of invasive procedures was 0.59 (0.77) per patient in the COVID-19 group compared with 1.18 (0.48)
per patient in the SOC group (adjusted difference, −0.54; 95% CI, −0.77 to −0.31). Both approaches
appeared to be safe and there was no significant difference in transfusion requirements, rebleeding,

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

rehospitalization, or in-hospital mortality. No mortality was attributed to GI bleeding in either group.
CONCLUSIONS AND RELEVANCE In this cohort study, first-line diagnostic evaluation of acute GI
bleeding using VCE appeared to be a safe and useful alternative to the traditional approach of upper
endoscopy and colonoscopy. Use of VCE was associated with increased detection of active bleeding
and a reduced number of invasive procedures and unnecessary exposure of personnel to SARSCoV-2 and use of personal protective equipment.
JAMA Network Open. 2021;4(7):e2118796. doi:10.1001/jamanetworkopen.2021.18796

Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2021;4(7):e2118796. doi:10.1001/jamanetworkopen.2021.18796 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Louisiana State University User on 11/30/2022

July 30, 2021

1/11

JAMA Network Open | Gastroenterology and Hepatology

Use of Video Capsule Endoscopy to Assess Acute GI Bleeding During COVID-19

Introduction
SARS-CoV-2, a single-stranded enveloped RNA virus, is responsible for the COVID-19 pandemic.1
SARS-CoV-2, found in the gastric, duodenal, and rectal epithelia of infected patients,2 can be
transmitted via aerosols, droplets, and physical contact.3,4 Esophagogastroduodenoscopy (EGD) and
colonoscopy, routinely used in the evaluation of gastrointestinal (GI) disorders, are both known to
produce aerosols, thus potentially exposing endoscopy personnel to SARS-CoV-2.4 However,
although many elective GI procedures can be deferred or canceled during surges of the pandemic,5
the evaluation of acute GI bleeding is often urgent and as such cannot be deferred. Current guidelines
recommend early EGD6 and/or colonoscopy7 within 24 hours as the first-line diagnostic and
therapeutic modalities for acute GI bleeding.
More recently, several studies have suggested a role for video capsule endoscopy (VCE) in the
management of acute GI bleeding.8-10 Video capsule endoscopy is a minimally invasive tool that does
not require sedation or GI manipulation and can visualize the upper, middle, and lower GI tract8
without generating aerosols. Reports suggest that VCE is more effective than conventional
endoscopy in detecting the site of active bleeding in many patients9 and hence serves as a valuable
tool in guiding further diagnostic and therapeutic interventions if needed. These changes in protocol,
prioritizing early VCE as a first-line diagnostic procedure, have been shown to be safe9,10 and well
tolerated. In this study, we sought to examine the use of VCE for the initial evaluation of suspected GI
bleeding in patients with suspected or established COVID-19 as a first-line tool to help minimize
patient and personnel exposure to SARS-CoV-2, limit unnecessary contacts, save personal protective
equipment (PPE), and avoid invasive and unnecessary procedures.

Methods
Design
We designed a multicenter retrospective cohort study aimed at assessing the comparative use of VCE
as a triaging tool as an alternative to standard of care (SOC) for evaluation of GI bleeding. The study
was conducted at UMass Memorial Medical Center and Louisiana State University Health Sciences
Center and approved by the institutional review boards at both institutions. Study personnel (S.H.,
M.H., L.S., M.P., and A.F.) collected data via review of medical records and completed data entry into
a standardized secure online database, Research Electronic Data Capture (REDCap),11 which was
hosted at UMass Memorial Medical Center. Demographic, clinical, and outcome data were collected
and analyzed. The institutional review boards for each facility granted a waiver of informed consent
for the patients receiving SOC, because this was retrospective data collection. The patients
undergoing VCE were regarded as receiving SOC and were not required to provide consent for the
study; rather, only routine informed consent for procedures was required by the institutional review
boards. The waiver also covered retrospective data collection for the VCE cohort. This study followed
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guideline.
The video capsule group included 74 patients with COVID-19 admitted between March 15 to
June 15, 2020, who underwent VCE as the first-line diagnostic modality for evaluation of GI bleeding.
A total of 72 historical controls were identified from January 1 to 31, 2020, a period before the known
spread of the COVID-19 pandemic in the US; these patients had undergone SOC. Inclusion criteria
for patients in both groups required that they be consecutive, hemodynamically stable adults (age
>18 years) with suspected GI bleeding as evidenced by the presence of melena, hematochezia,
hematemesis, and/or severe anemia. Patients who developed signs and symptoms of GI bleeding
during their hospitalization for other indications were also included. Exclusion criteria for VCE
included dysphagia, gastroparesis, previous intestinal surgery, abdominal radiotherapy, and the
presence of an implantable cardiac device. Patients were followed up for 30 days after their episode
of GI bleeding for assessments of rebleeding and mortality.
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Invasive procedures included EGD, colonoscopy, enteroscopy, conventional angiography, and
surgery. Diagnostic procedures were defined as any of the abovementioned invasive procedures and
computed tomographic angiography and VCE, which we defined as minimally invasive. An upper
source of bleeding was defined to be within the reach of an EGD, a middle source as a small intestinal
bleed beyond the second portion of the duodenum, and a lower source as a colonic source of
bleeding. A presumptive source was defined as any lesions or blood typically associated with a
bleeding source with or without signs of active bleeding or stigmata of bleeding.
Both centers used the PillCam SB 3 and RAPID software, version 8.00 or higher (both
Medtronic). Patients fasted for 6 to 8 hours before capsule ingestion per standard protocol. Patients
then swallowed the capsule with 118 to 237 mL of water. No purgative bowel preparation was used.
The real-time viewer was used immediately after ingestion to check for blood in the stomach and
again within a few hours to check for bleeding in the small intestine. If bleeding was noted, the study
was truncated, data were downloaded from the recorder, and a video created on a workstation was
reviewed to determine the exact source of bleeding. If no blood was seen on the initial review, the
capsule was allowed to record for up to 12 hours before download and review.
The primary end point of the study was detection of active bleeding or stigmata of recent
hemorrhage. Secondary end points included the number of patients undergoing invasive
procedures, number of additional procedures needed for evaluation, rates of rebleeding and
rehospitalization, transfusion requirements, and rates of mortality.
To perform VCE, we assumed 1 staff member, albeit for a brief encounter, aided the patient in
swallowing the video capsule and later collected and cleaned the equipment. For EGD, colonoscopy,
and enteroscopy, we assumed 4 staff members were present during the procedure, which included
the endoscopist, endoscopy nurse, endoscopy technologist, and anesthesia staff. We assumed no
trainee involvement and no additional preprocedure and postprocedure staff for this estimate.

Statistical Analysis
Patient characteristics are described as means (SDs) or as percentages. Continuous variables were
analyzed using t test and binary variables were analyzed using χ2 or Fisher exact tests. Multivariate
logistic and linear regression estimated adjusted odds ratios (ORs) or differences of means for
primary and secondary outcomes. As a secondary analysis, the primary and secondary outcomes
were compared in propensity score–matched patients. Key variables with a standardized difference
in absolute value greater than 0.15 were considered for matching. Propensity scores were estimated
using a logistic regression model for the COVID-19 vs SOC cohorts that included age, sex, race/
ethnicity, Glasgow-Blatchford score, cirrhosis, and kidney failure. One-to-one matching within center
using a caliper of 0.15 maximized the sample size (n = 54 per arm) while balancing the key
characteristics (eTable 2 in the Supplement). For the primary outcome of active bleeding, secondary
analyses included a multivariable-adjusted OR (COVID-19 vs SOC) in the population on common
support of the propensity score, and in the matched population adjusted for characteristics with
standardized difference greater than 0.15 in absolute values. Sample size was based on data from 2
randomized clinical trials.8,12 With 70 patients per group, there would be greater than 80% power for
differences in rates of active bleeding detection of 25% or for ORs of 3.0 or greater. The significance
threshold was α = .05; all tests were 2 sided where appropriate. Unpaired t test, Fisher exact test,
logistic regression, and linear regression assumed independent samples. Statistical analysis was
conducted with Stata, version 16.1 (StataCorp LLC).

Results
The study included a total of 146 patients, with 74 patients in the COVID-19 group and 72 patients in
the SOC group. Of these, 118 patients were enrolled from UMass Memorial Medical Center and 29
from Louisiana State University. A total of 92 (63.0%) of the patients were men and 54 (37.0%) were
women; mean (SD) age was 64.93 (14.13) years in the COVID-19 group and 61.33 (13.39) years in the
JAMA Network Open. 2021;4(7):e2118796. doi:10.1001/jamanetworkopen.2021.18796 (Reprinted)
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SOC group; Table 1 includes baseline characteristics that were assessed for potential inclusion in the
propensity score (eTable 1 in the Supplement includes the list of all baseline characteristics collected
in the overall population). Matching resulted in 54 patients in each group (eTable 2 in the
Supplement). The analysis of results for the overall population and the matched population is
summarized in Table 2 along with secondary analyses of the primary outcome (eTable 3 in the
Supplement). As defined by the study objectives, all 74 patients in the COVID-19 group underwent
VCE as the first procedure. In the SOC group, 60 patients (83.3%) underwent EGD, 9 (12.5%)
underwent colonoscopy, and 3 (4.2%) underwent VCE as the first procedure (Table 3).

Outcomes
For the primary outcome, active bleeding was detected in 44 patients (59.5%) in the COVID-19 group
compared with 18 (25.0%) in the SOC group (OR, 5.23; 95% CI, 2.23-12.27) (Table 2). When the
patient population was matched by propensity scoring, the OR decreased slightly to 4.75 (95% CI,
2.02-11.14). A presumed bleeding source was identified using the first diagnostic modality in 55
patients (74.3%) in the COVID-19 group compared with 46 patients (63.9%) in the SOC group (OR,
1.85; 95% CI, 0.81-4.20).
In the overall population, only 36 (48.7%) patients in the COVID-19 group underwent any
invasive procedures compared with 70 (97.2%) in the SOC group (adjusted OR, 0.01; 95% CI, 0.001
to 0.08). The mean (SD) number of invasive procedures was 0.59 (0.77) per patient in the COVID-19
group compared with 1.18 (0.48) per patient in the SOC group (adjusted difference, −0.54; 95% CI,
−0.77 to −0.31). The mean (SD) number of diagnostic procedures was 1.62 (0.86) per patient in the
COVID-19 group compared with 1.30 (0.57) per patient in the SOC group (adjusted difference, 0.34;
95% CI, 0.085 to 0.59). There was no statistically significant difference in the rates of rebleeding,
inpatient mortality, hemoglobin level decrease, or units of packed red blood cell transfusions in the

Table 1. Baseline Characteristics and Matched Variables in the Overall Population
Characteristic

COVID-19, No. (%) (n = 74)

SOC, No. (%) (n = 72)

Standard difference

Female

29 (39.2)

25 (34.7)

0.092

Male

45 (60.8)

47 (65.3)

64.93 (14.13)

61.33 (13.39)

0.261

White

49 (66.2)

40 (55.6)

0.218

African American

12 (16.2)

16 (22.2)

−0.152

Hispanic

4 (5.4)

6 (8.3)

−0.115

Othera

9 (12.2)

10 (13.9)

−0.051

Cirrhosis

13 (17.6)

17 (23.6)

−0.149

Kidney failure

5 (6.8)

4 (5.6)

0.05

Hematemesis

8 (10.8)

11 (15.3)

−0.132

Melena

35 (47.3)

27 (37.5)

0.198

Hematochezia

3 (4.1)

16 (22.2)

−0.555

Anemia

28 (37.8)

18 (25)

0.277

Nonsteroidal anti-inflammatory
drugs

9 (12.2)

14 (19.4)

−0.199

Aspirin

33 (44.6)

27 (37.5)

0.144

P2Y12 inhibitor

10 (13.5)

8 (11.1)

0.073

Warfarin

14 (18.9)

8 (11.1)

0.218

Direct oral anticoagulant

10 (13.5)

4 (5.6)

0.272

Heparin

2 (2.7)

2 (2.8)

−0.005

No anticoagulant

33 (44.6)

39 (54.2)

−0.191

8.43 (2.36)

7.56 (2.90)

0.331

Sex

Age, mean (SD), y
Race/ethnicity

Presenting symptom

Medications
Abbreviation: SOC, standard of care.

b

Glasgow-Blatchford score, mean (SD)
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46 (63.9)
70 (97.2)
1.18 (0.48)
1.30 (0.57)
4.78 (1.90)

Any invasive procedures, No. (%)

Invasive procedures, mean (SD)

Total diagnostic procedures, mean (SD)

PPE use, mean (SD)

2.28 (2.48)
10 (13.9)
7 (9.7)
2 (2.8)

Units pRBC transfused, mean (SD)

Rebleeding, No. (%)

Readmission for bleeding, No. (%)

In hospital mortality, No. (%)

3 (4.1)

10 (13.5)

12 (16.2)

2.57 (3.23)

3.72 (1.90)

3.38 (3.10)

1.62 (0.86)

0.59 (0.77)

36 (48.7)

55 (74.3)

44 (59.5)

COVID-19 (n = 74)

>.99

.61

.82

.55

.92

.001

.01

<.001

<.001

.21

<.001

P value a

1.57 (0.20 to 12.12)

1.59 (0.48 to 5.24)

1.51 (0.53 to 4.23)

−0.139 (−1.09 to 0.81)

−0.25 (−0.97 to 0.47)

−1.23 (−2.12 to −0.33)

0.34 (0.085 to 0.59)

−0.54 (−0.77 to −0.31)

0.01 (0.001 to 0.08)

1.85 (0.81 to 4.20)

5.23 (2.23 to 12.27)

4.59 (2.00 to 10.49)

Adjusted for sex; age; race; Glasgow-Blatchford score; use of nonsteroidal anti-inflammatory drugs, aspirin, warfarin, and direct oral anticoagulants; no anticoagulation; cirrhosis; kidney failure; and presenting symptoms.

1 (0.14 to 7.37)

1.34 (0.46 to 3.91)

1.28 (0.48 to 3.39)

−0.06 (−1.23 to 1.12)

−0.28 (−1.01 to 0.45)

−1 (−2.02 to 0.02)

0.39 (0.09 to 0.69)

−0.48 (−0.74 to −0.23)

0.04 (0.01 to 0.16)

1.86 (0.81 to 4.20)

The P values for active bleeding and presumed source of bleeding were analyzed using the Fisher exact test (categorical variables). The other P values were analyzed using the t test (continuous variables).

>.99

.797

.81

.93

.45

.06

.01

<.001

<.001

.21

<.001

Adjusted OR/difference (95% CI)b

b

2 (3.7)

9 (16.7)

11 (20.4)

2.50 (3.53)

3.44 (1.76)

3.52 (3.41)

1.67 (0.95)

0.63 (0.85)

26 (48.2)

41 (75.9)

32 (59.3)

P valuea

a

SI conversion: To convert hemoglobin to grams per liter, multiply by 10.

2 (3.7)

7 (13.0)

9 (16.7)

2.56 (2.52)

3.72 (2.06)

4.52 (1.63)

1.28 (0.56)

1.11 (0.42)

52 (96.3)

34 (63.0)

13 (24.1)

COVID-19 (n = 54)

Matched population
Adjusted OR/difference (95% CI)b SOC (n = 54)

Abbreviations: OR, odds ratio; PPE, personal protective equipment; pRBC, packed red blood cell; SOC, standard of care.

3.68 (2.26)

Change in hemoglobin, mean (SD), g/dL

Safety

18 (25.0)

Presumed source of bleeding on initial test, No. (%)

SOC (n = 72)

Overall population

Active bleeding visualized, No. (%)

Main outcomes

Variable

Table 2. Main Treatment Outcomes and Safety for Overall and Matched Populations
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overall population or the matched population (Table 2). There was no mortality attributed to GI
bleeding in either group.
The matched population, but not the overall population, showed a significant difference in
localization of bleeding (Table 4). When analyzed separately against other localizations, the
COVID-19 group showed higher rates of bleeding in the midgut compared with the SOC group (11 of
74 [15%; 95% CI, 7.7%-25.0%] vs 2 of 72 [3%; 95% CI, 0.3%-9.7%]). Distribution of the type of lesion
identified also differed (P < .001 in overall; P < .001 in matched). Angioectasias were the most
common finding (18 [24%]) in the COVID-19 group; peptic ulcer disease was most common in the
SOC group (22 [31%]) (Table 4).
Based on assumptions described earlier, we estimated 250 personnel encounters and sets of
PPEs used for endoscopic evaluation of patients in the COVID-19 group (mean [SD], 3.38 [3.10]
PPE/patient) compared with 344 personnel encounters and sets of PPEs in the SOC group (mean
[SD], 4.78 [1.90] PPE/patient) (adjusted difference, −1.23; 95% CI, −2.12 to −0.33) (Table 2). This
calculation was associated with an estimated 30% reduction in the overall use of PPE.

Table 3. Number of Procedures in Each Treatment Group
Procedures

COVID-19, No. (%) (n = 74)

SOC, No. (%) (n = 72)

First diagnostic procedure
EGD

0

60 (83.3)

Colonoscopy

0

9 (12.5)

VCE

74 (100)

3 (4.2)

Total procedures
EGD

21 (28.4)

61 (84.7)

Colonoscopy

9 (12.2)

21 (29.2)

VCE

74 (100)

6 (8.3)

Enteroscopy

8 (10.8)

1 (1.4)

CT angiogram

0

2 (2.8)

Surgery

1 (1.4)

2 (2.8)

Abbreviations: CT, computed tomography; EGD,
esophagogastroduodenoscopy; SOC, standard of care;
VCE, video capsule endoscopy.

Table 4. Bleeding Localization and Lesion Type
Overall population
Variable

Matched population

COVID-19 (n = 74)

SOC (n = 72)

Upper GI

35 (47)

38 (53)

Midgut

11 (15)

2 (3)

Lower GI

11 (15)

Peptic ulcer
Angioectasia
Blood without discrete lesion

P value

COVID-19 (n = 54)

SOC (n = 54)

24 (44)

31 (57)

P value

Bleeding localization, No. (%)

10 (18)

2 (4)

11 (15)

9 (17)

4 (7)

15 (20)

22 (31)

10 (19)

18 (33)

18 (24)

5 (7)

15 (28)

5 (9)

8 (11)

2 (3)

5 (9)

1 (2)

Dieulafoy

3 (4)

1 (1)

2 (4)

1 (2)

Varices

1 (1)

4 (5)

1 (2)

3 (6)

Mallory-Weiss tear

0

2 (3)

0

2 (4)

.08

.03

Type of lesion, No. (%)

<.001

Diverticulosis

0

5 (7)

0

3 (6)

Portal hypertension

4 (5)

1 (1)

4 (7)

1 (2)

Other

9 (12)

8 (11)

6 (11)

16 (29)

<.001

Abbreviations: GI, gastrointestinal; SOC, standard of care.
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Discussion
In this cohort study, we noted that the initial use of VCE as an alternative to the traditional, more
invasive diagnostic evaluation of GI bleeding with EGD and/or colonoscopy appeared to be safe
during the COVID-19 pandemic. When used early, VCE as the first strategy was associated with
improved localization of active bleeding and reduced the number of urgent invasive endoscopic
evaluations without increasing the risk of complications. In addition, VCE as the first strategy was
associated with reduced staff use, and thereby reduced risk of exposure to endoscopic aerosols and
conserved PPE.
Using VCE as a triaging tool before endoscopic evaluation is a new frontier in the management
of GI bleeding described in recent randomized clinical trials.9,12 The data presented herein are
consistent with an earlier observation in nonhematemesis GI bleeding that showed improved
localization of the anatomic source of bleeding in 64% of patients in the VCE group compared with
31% in the SOC group.9 Previous data have shown that patients can be risk stratified using a
combination of VCE data and clinical parameters and safely discharged if there is no evidence of
active, ongoing bleeding. Therefore, in this setting, VCE serves as a triaging tool for endoscopic
localization and to help determine the need for further invasive endoscopic intervention, because
clinical history alone can be imprecise in localization and VCE provides additional clinical information
beyond nasogastric tube aspiration13 and the Glasgow-Blatchford or Rockall scoring systems.14,15
Although current guidelines recommend early endoscopy within 24 hours for acute GI bleeding,
studies have suggested that some invasive procedures can be safely deferred in the acute setting in
carefully selected stable patients. A recent meta-analysis by Tsay and colleagues16 suggested that
colonoscopy within 24 hours did not decrease the risk of rebleeding or mortality in patients
hospitalized with acute lower GI bleeding. A similar study by Aziz and colleagues17 compared EGD
within 24 hours of presentation to EGD after 24 hours of presentation and found no significant
difference in mortality, recurrent bleeding, or length of stay. Because previous studies suggest that
the yield of VCE is higher if the procedure is performed earlier,10,18 our findings presented herein
suggest that earlier use of VCE along with clinical parameters may aid in risk stratifying patients who
might require more urgent intervention vs those who can likely await further outpatient evaluation.
In our study, although there was a significant difference in the identification of active bleeding
or stigmata of recent bleeding in the COVID-19 group, there was no statistically significant difference
in attribution to a presumptive source of bleeding between the 2 groups, although the rate was still
numerically higher in the COVID-19 group compared with the SOC group. A presumptive source of
bleeding, common with the traditional approach to evaluation of GI bleeding, should be viewed with
appropriate clinical skepticism to avoid premature closure. Bleeding attributed to findings such as
small, clean-based ulcers, esophagitis,19 or diverticular disease20,21 without stigmata of active
bleeding should be viewed within the proper clinical context to avoid easily missed diagnoses, such
as Cameron lesions,22 Dieulafoy lesions,23 or small bowel lesions.18 Given the increased rates of
detection of active bleeding or stigmata of bleeding and hence potentially better localization with
early deployment of VCE as noted in this study and others, VCE potentially provides additional
benefits via a more complete view of the GI tract.18
As noted, VCE use has additional advantages over SOC. Endoscopy during the COVID-19
pandemic provides additional challenges for infection control, limited PPE availability,24 and need for
staff redeployment.25 Traditional endoscopic procedures involve multiple personnel, including the
endoscopist, the endoscopy nurse, technicians, anesthesia staff, and trainees. Additional staff help
with the patient’s preoperative assessment, recovery, processing of equipment, room turnover, and
cleaning.26,27 To mitigate infectious risks, some centers, including both study sites, adopted policies
such as canceling nonurgent procedures,28 prophylactic intubation of COVID-19–positive patients
undergoing endoscopy, limited trainee participation, and reduced number of staff involved.
However, prophylactic intubation has been associated with increased rates of bacterial pneumonia29
and prolonged intubation, and limiting trainee participation can reduce learning opportunities.30
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In contrast, VCE is particularly suitable for triaging and diagnostic evaluation of patients with
suspected or established COVID-19 because it requires no sedation or endotracheal intubation and
minimal patient contact is needed to help set up equipment without contact with the oropharyngeal
or gastrointestinal mucosa. In addition, the video capsule is disposable, and the recording equipment
can be easily covered and cleaned after use. The advent of the real-time viewers built into the
recording equipment allows quick real-time evaluation31 of the stomach and upper GI tract within
minutes to help triage patients who would benefit from further therapeutic or additional diagnostic
evaluations. Use of VCE in the COVID-19 setting is not a substitute for appropriate less-urgent
screening or surveillance programs for cancer or other diagnostic evaluations, which can safely be
deferred for conventional endoscopy. However, VCE is a useful tool to detect active bleeding or
stigmata of recent hemorrhage and, combined with other clinical data, can be used in deciding the
need for site-directed endoscopy.
Video capsule endoscopy has the disadvantage of being a passive device that cannot be
manipulated after ingestion, but this is a small disadvantage because the goal is not necessarily to
reach an exact diagnosis, but rather to risk stratify and triage patients who may benefit from
additional therapeutic interventions. Furthermore, VCE is currently a purely diagnostic test that does
not offer therapeutic options—a disadvantage compared with EGD and colonoscopy. However, it has
been shown that many patients do not need therapeutic interventions and can be spared from these
invasive procedures, at least in the acute setting.12 Our findings herein are consistent with those
reported in a randomized clinical trial in which active bleeding was detected more than twice as
frequently by VCE than SOC and 80% of patients12 reporting hematemesis could safely be
discharged for subsequent outpatient evaluation.
Although a full cost analysis was outside the scope of this study, it is reasonable to estimate that
there would be a potential associated reduction in expenses by decreased use of procedures and
PPE. In a previous cost analysis of the use of early VCE in nonhematemesis GI bleeding, Jawaid and
colleagues32 found no significant difference in total direct costs between patients who underwent
early VCE compared with SOC. However, the costs were more efficiently distributed in the VCE group
toward detection and treatment of bleeding, whereas in the SOC group, costs were incurred without
obtaining a definitive diagnosis. Furthermore, Jawaid and colleagues projected that a more
aggressive, albeit safe, discharge strategy could result in a 50% reduction in length of stay in the VCE
vs SOC group (0.88 vs 1.63 days), with an associated decrease in direct costs attributed to less
patient time spent in the hospital and less time occupying a bed. These potential savings are likely to
be expanded in the COVID-19 era, owing to the costs of PPE and additional costs incurred for added
hospital stays due to testing requirements (COVID-19 testing) before many endoscopic procedures
requiring sedation.

Limitations
This study had several limitations. First, by its design, as necessitated by limitations during the
COVID-19 pandemic, this was a retrospective study, which raises the potential for selection bias and
lack of blinding. Herein, we have used propensity score matching to adjust for some of these
differences. Larger, multicenter, prospective randomized clinical trials are necessary to generalize the
results to other populations. Second, there was a disproportionate number of patients with
hematochezia in the SOC group, which raises a question of bias. Despite this difference, a similar
number of patients had lesions localized to the colon in both groups, most prominently in the
proximal colon in the VCE group, arguing that not all right colonic bleeds are being identified by the
SOC approach, either due to delay or the preparation for colonoscopy.

Conclusions
The findings of this cohort study suggest that the initial use of VCE as an alternative to the traditional,
more invasive diagnostic evaluation of GI bleeding with EGD and/or colonoscopy appeared to be a
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safe and useful alternative in the era of the COVID-19 pandemic. The use of VCE vs SOC was
associated with a higher detection rate of stigmata of bleeding, reduced use of traditional endoscopic
procedures requiring sedation, and reduced personnel and PPE use without a significant increase in
transfusion requirements, rebleeding rates, or mortality.
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